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S U M M A R Y
Patients infected with HIV have a high prevalence of thiamine deﬁciency. Genetic studies have provided
the opportunity to determine which proteins link thiamine to HIV pathology, i.e., renin–angiotensin
system, poly(ADP-ribosyl) polymerase 1, Sp1 promoter gene, transcription factor p53, apoptotic factor
caspase 3, and glycogen synthetase kinase 3b. Thiamine also affects HIV through non-genomic factors,
i.e., matrix metalloproteinase, vascular endothelial growth factor, heme oxygenase 1, the prostaglandins,
cyclooxygenase 2, reactive oxygen species, and nitric oxide. In conclusion, thiamine may beneﬁt HIV
patients, but further investigation of the role of thiamine in HIV infection is needed.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Nutritional status has been related to disease development in
patients infected with HIV. The dietary intake of vitamin C,
thiamin, and niacin has been associated with a signiﬁcantly slower
progression to AIDS in homosexual men infected with HIV type 1.1
Daily multivitamin use has been associated with a reduced risk of
AIDS and a signiﬁcantly reduced risk of low CD4 counts at baseline
in HIV-positive homosexual men.2 Taking multivitamin supple-
ments during pregnancy improves weight gain and postnatal child
growth, and reduces the risk of hypertension and adverse
pregnancy outcomes in HIV-infected women.3–6 Thiamine and
vitamin B6 supplements at more than twice the recommended
dietary allowance have been associated with improved survival in
HIV-infected patients.7 Severe thiamine deﬁciencies, such as
Wernicke encephalopathy and beriberi disease, are also observed
in HIV patients.8–11 Thiamine deﬁciency has been found in a large
percentage of HIV-positive patients.12–14 Long-term side effects,
such as thiamine deﬁciency and lactic acidosis, have been found in
HIV-infected patients using nucleoside reverse transcriptase
inhibitors (NRTIs). Thiamine supplementation has been effective
in treating NRTI-induced lactic acidosis.15–19 Furthermore, treating
Schizosaccharomyces pombe expressing HIV-1 viral protein R with a
low concentration of hydrogen peroxide and 0.1 mmol/l thiamine
signiﬁcantly increased both the human cell proliferation and* Corresponding author. Tel.: +1 714 839 5898; fax: +1 714 839 5989.
E-mail address: Lng2687765@aol.com (K.v.q. Lu’o’ng).
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cells.20 Prosultiamine, a disulﬁde thiamine derivative, induced
caspase-dependent apoptosis against human T-lymphotropic virus
type 1 (HTLV-1) cells and signiﬁcantly decreased the HTLV-1
proviral copy numbers to approximately 30–50% of their
pretreatment levels in patients with HTLV-1-associated myelopa-
thy/tropical spastic paruresis.21 A trans-disulﬁde of thiamine
disulﬁde suppresses HIV-1 replication by preventing the nuclear
translocation of both HIV-1 Tat and nuclear factor kappaB (NF-
kB).22 Thiamine disulﬁde markedly inhibited the production of
progeny HIV-1 in acutely and chronically HIV-1-infected cells.23
These results suggest a relationship between thiamine and HIV.
Therefore, we review the role of thiamine in HIV infection.
2. Genetic factors related to thiamine in HIV
The primary function of the renin–angiotensin system (RAS) is
to maintain ﬂuid homeostasis and regulate blood pressure.
Angiotensin-converting enzyme (ACE), a key enzyme in the RAS,
converts angiotensin I to the potent vasoconstrictor angiotensin
II.24 Serum ACE levels have been found to be signiﬁcantly elevated
in AIDS patients, patients in the intermediate stage of HIV
infection, and patients with Pneumocystis carinii pneumonia.25,26
Captopril, an ACE inhibitor, may offer long-term renal survival
beneﬁts in HIV-associated nephropathy in animals and humans if
the treatment is initiated prior to severe renal inefﬁciency.27–29 An
ACE inhibitor has also been shown to improve the mean velocity of
circumferential ﬁber shortening and peak systolic left-ventricular
wall stress in HIV-infected children.30 HIV-positive patients whoses. Published by Elsevier Ltd. All rights reserved.
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platelet activation that are potentially reversible with ACE
inhibitor therapy.31 Moreover, T-cell stimulation by HIV-1
gp160-derived peptide p18 (presented by HLA class I molecules
in a cell-free system) has been found to require proteolytic
cleavage, which is blocked by captopril.32 An interaction between
thiamine and the RAS has been observed. Thiamine deﬁciency
signiﬁcantly depresses plasma and urinary aldosterone responses
to sodium deprivation in rats.33 Thiamine attenuates hypertension
and metabolic abnormalities in spontaneously hypertensive rats
(SHRs). Thiamine repletion downregulates the expression of
angiotensinogen (80%), ACE (77%), and angiotensin type 1
receptor (72%) mRNAs in SHRs.34 These observations suggest that
thiamine affects ACE activity in HIV-infected patients.
Poly(ADP-ribosyl) polymerase 1 (PARP-1) is a nuclear protein
present in mammalian cells and has been observed to regulate
various biological activities. PARP-1 plays an important role in
tissue injury in conditions associated with oxidative stress and
inﬂammation. In HIV-infected cells, increased PARP-1 activity and
accentuated fragmentation of cellular DNA are associated with
HIV-1 replication.35 In the brains of autopsied AIDS patients,
immune-staining for PARP was found to be more intense in the
gray and white matter of patients with HIV encephalitis.36 PARP-1
is required for efﬁcient HIV-1 integration; PARP-1 knockout
ﬁbroblasts were found to be nearly completely protected from
HIV-1 infection.37,38 Established small interference RNA (siRNA)
against PARP-1 was found to signiﬁcantly suppress HIV-1
replication, as well as the activation of the integrated HIV-1 long
terminal repeat (LTR) promoter.39 Thiamine has a cytoprotective
effect on cultured neonatal rat cardiomyocytes under hypoxic
insult; it also inhibits PARP cleavage and DNA fragmentation.40
Benfotiamine, a fat-soluble thiamine analog, also prevents
bacterial endotoxin-induced inﬂammation and PARP cleavage in
mouse macrophage cell lines.41 Adenosine thiamine triphosphate
(ATTP), a new thiamine derivative, has been identiﬁed in small
amounts in the mouse brain, heart, skeletal muscle, liver, and
kidneys,42 and has been shown to inhibit PARP-1 activity.43
Vpr is an HIV-1 virion protein that plays a role in enhancing
HIV-1 replication in vivo. Vpr interacts with transcription factor
Sp1 when Sp1 is bound to the Sp1 motifs within the HIV-1 LTR, and
Vpr transactivation through Sp1 is critical for the immediate early
transcription of HIV-1.44 An interaction between NF-kB and Sp1 is
required for inducible HIV-1 gene expression and may activate
speciﬁc viral and cellular genes.45 Sp1 and Sp3 regulate the basal
transcription of the ABOBEC3G gene, which is expressed in
peripheral blood lymphocytes and has activity against HIV-1
and other retroviruses.46 Mutation of the Sp1 sequence impairs
both multimerization and the membrane-binding activities of HIV-
1 Gag.47 Thiamine uptake in the human intestine occurs via a
specialized carrier-mediated mechanism, and the human thiamine
transporters (THTRs) are expressed in the intestine and are
regulated via Sp1 promoter elements.48,49
The p53 gene and protein play critical roles in regulating the
normal cell cycle, cell cycle arrest, and apoptosis. p53 expression
and activation have been associated with faster disease progres-
sion in HIV-infected patients. Thakur et al.50 provided evidence
that the cell-killing effect of the HIV-1 viral protein Tat is mediated
by activating the p53 pathway. In one experiment, p53 was fused
with HIV Tat protein; the fusion product can cross cell membranes
and inﬂuences HepG2 cell apoptosis.51 The HIV-1-mediated
increase in p53 gene expression is associated with the virus-
mediated induction of type I interferon in human primary CD4 + T
cells.52 Tat contributes to neuronal degeneration by activating
a pathway that involves the p53 and p73 transcription factors
in neuroAIDS.53 Activation of the p53-mediated pathways in
the glia of HIV-associated dementia patients contributes to theneuroinﬂammatory processes that promote neurodegeneration by
inhibiting glial proliferation and/or promoting glial cell dysfunc-
tion.54 Vpr protein and transcript have been shown to be present in
the brains of HIV-infected patients. Moreover, soluble Vpr caused
neuronal apoptosis, cytochrome c extravasation, p53 induction,
activation of caspase 9, and a depressive effect on the whole-cell
currents in the neurons.55 In contrast, an increased number of
thiamine transporters are observed in cells that overexpress
thiamine transport genes (mTHTR-1) and in cells that are exposed
to conditions that induce DNA damage or p53 activation.56
Thiamine diphosphate inhibits p53 binding, and thiamine inhibits
intracellular p53 activity.57 Thiamine treatment signiﬁcantly
decreases p53 expression in the cultured retinal neurons from
diabetic rats.58 These observations suggest that the pro-apoptotic
transcription factor p53 is activated by cellular damage in HIV
infection and that thiamine ameliorates these effects.
Caspases are cysteinyl aspartate-speciﬁc proteases that play a
critical role in the regulatory and execution phases of apoptosis.59
The overexpression of caspase 3 has been observed in the brains of
pediatric patients with HIV-1 encephalitis.60 The induction of
apoptosis by HIV-1 envelope proteins gp120/160 in cultured
endothelial cells is mediated by caspase 3 and cleavage of focal
adhesion kinase in primary human CD4+ T cells.61,62 HIV gp41-
induced apoptosis is mediated by caspase 3-dependent mitochon-
drial depolarization, which is inhibited by the HIV protease
inhibitor nelﬁnavir but not by other HIV protease inhibitors or
inhibitors of calpain and cathepsin.63 A potent and selective HIV-1
reverse transcriptase inhibitor, 30-azido-20,30-deoxythymidine
(AZT) is widely used in antiretroviral therapy. AZT inhibits
visna/maedi virus-induced apoptosis and diminishes the activity
of caspases 3, 8, and 9;64 however, breast cancer cells that are
transfected with the thiamine transporter SLC19A3 gene show an
increase in apoptosis when they are exposed to doxorubicin and
radiation, and the caspase 3-dependent pathway partially med-
iates this effect.65 The thiamine deﬁciency caused by thiamine
antagonists leads to caspase 3 apoptosis in the neuronal
differentiated PC-12 cells of rats.66 Thiamine has a cytoprotective
effect on cultured neonatal rat cardiomyocytes against hypoxia-
induced apoptosis; it also inhibits caspase 3 activation.40
Benfotiamine accelerates healing in the ischemic diabetic limbs
of mice by potentiating angiogenesis and preventing the induction
of pro-apoptotic caspase 3.67 Sulbutiamine, a highly lipid-soluble
synthetic analog of thiamine, attenuates trophic factor depriva-
tion-induced cell death in transformed retinal ganglion cells (RGC-
5) and decreases the expression of cleaved caspase 3.68 These
ﬁndings suggest that thiamine may inﬂuence HIV infection by
inhibiting the activity of the apoptotic factor caspase 3.
Glycogen synthetase kinase 3b (GSK3b) is a protein kinase that
is involved in many physiological processes, e.g., metabolism, gene
expression, and apoptosis. The HIV-1 Tat-mediated activation of
GSK3b contributes to Tat-mediated neurotoxicity69 and antag-
onizes the NF-kB survival pathway in neurons.70 GSK3b-speciﬁc
inhibitors, such as AR-A014418 and B6B30, prevent direct
neurotoxicity in primary human neurons exposed to HIV.71
Exposure to pyrithiamine, an anti-thiamine compound, also
increases the b-amyloid protein accumulation and GSK3 activity
in the brain.72 Benfotiamine was shown to improve cognitive
function, reduce amyloid deposition, and suppress GSK3 activity in
an animal model of Alzheimer’s disease.73 These ﬁndings suggest
that thiamine may inﬂuence HIV by suppressing GSK3 activity.
3. The non-genetic role of thiamine in HIV
Matrix metalloproteinases (MMPs) are proteolytic enzymes
that are responsible for extracellular matrix remodeling and for
regulating of leukocyte migration through the extracellular matrix,
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infectious diseases. MMPs are produced by many cell types
including lymphocytes, granulocytes, astrocytes, and activated
macrophages. There is an increased concentration of MMPs 1, 3, 7,
8, 9, 25, and 26 in the saliva and gingival tissue of HIV-infected
patients.74,75 Gingival mast cells have also been shown to strongly
express MMP-1 and MMP-8 in HIV-infected patients.76 MMP-9
was found to be overexpressed in the glomeruli of a patient with
HIV-associated nephropathy.77 Maternal HIV-1 infection sup-
presses MMP-1 expression in the endothelial cells of uninfected
newborns and may contribute to the impaired cardiac function
observed in these newborns.78 Increased levels of serum MMP-1
and MMP-7 are correlated with micro-structural brain alterations
and brain atrophy.79 Elevated cerebrospinal ﬂuid levels of MMP-2,
MMP-7, and MMP-9 are correlated with HIV dementia.80 In a rat
model of human HIV-related encephalopathy, MMP-2 and MMP-9
were upregulated by the HIV envelope gp120.81 Increased levels of
MMP-2 were found in plasma from patients with AIDS-related
Kaposi’s sarcoma.82 No MMP-9 activity was detected after
antiretroviral therapy in the HIV-infected subjects.83 Treatment
with both zidovudine and indinavir was found to inhibit the
expression of MMP-2 in astrocytes, but these anti-HIV drugs
decreased the expression of MMP-9 in both astrocytes and
microglia.84 MMP-9 is also upregulated in the TD mouse brain.85,86
Thiamine prevents diabetes-induced cardiac ﬁbrosis and decreases
MMP-2 activity in the hearts of diabetic rats.87 Moreover, thiamine
and benfotiamine correct the increase in MMP-2 activity that
results from high glucose levels in human retinal pericytes, while
increasing TIMP-1.88 Fursultiamine, a vitamin B1 derivative, was
found to enhance the chondro-protective effects of glucosamine
hydrochloride and chondroitin sulfate and reduce MMP-1 levels in
rabbit experimental osteoarthritis.89
Angiogenesis is a complex process that involves coordinated
endothelial cell activation, proliferation, migration, and tube
formation, as well as capillary sprouting. In addition, angiogenesis
requires the participation of numerous intracellular signaling
pathways. Vascular endothelial growth factor (VEGF) is a key
mediator of angiogenesis. The HIV Tat protein plays a key role in
vascular cell activation and is a heparin-binding angiogenic growth
factor.90 Tat induces the growth of Kaposi’s sarcoma spindle cells
and is angiogenic in vivo and in transgenic mice. Tat speciﬁcally
binds and activates the Flk-1/kinase insert-domain receptor (Flk-1/
KDR) and a VEGF-A tyrosine kinase receptor. Tat-induced
angiogenesis is blocked by the agents blocking the Flk-1/KDR
receptor.91 VEGF-mimetic HIV-1 Tat is connected to increased
microvessel density in AIDS-related diffuse large B cell and
Burkitt’s lymphomas.92 The AIDS Kaposi’s sarcoma cell lines
express higher levels of VEGF than either human umbilical vein
endothelial cells or human aortic smooth muscle cells.93 The VEGF
plasma levels increase in AIDS patients with Kaposi’s sarcoma
compared to HIV-1-infected persons without Kaposi’s sarco-
ma.94,95 In HIV-associated central nervous system (CNS) diseases,
the VEGF levels increase in the serum but not in the CSF.96 VEGF is a
potent angiogenic factor in AIDS-associated Kaposi’s sarcoma-
derived spindle cells.97 Tat induces human monocyte chemotaxis
by activating the VEGF receptor 1.98 The HIV-1 induction of VEGF
expression in podocytes may be a critical step in the pathogenesis
of HIV-associated nephropathy.99 HIV protease inhibitors decrease
VEGF expression and angiogenesis in glioblastoma cells.100
Moreover, thiamine deﬁciency has been shown to result in
polyneuropathy after a gastrectomy; this deﬁciency has also been
associated with high levels of serum VEGF. VEGF levels typically
return to normal following the intravenous administration of
thiamine, which further improves the symptoms of polyneuro-
pathy.101 In addition, increased serum levels of VEGF have been
reported in patients with wet beriberi.102 In a model of peritonealdialysis in uremic rats, treatment with benfotiamine decreased
peritoneal ﬁbrosis, markers of inﬂammation, neovascularization,
and VEGF staining.103 Furthermore, benfotiamine has also been
shown to improve the functional recovery of infarcted hearts and
reduce the phosphorylation/activation of the VEGF receptor 2/Akt
signaling pathways in a mouse macrophage cell line.104
Heme oxygenase-1 (HO-1) is a stress protein that may confer
cytoprotection by enhancing the catabolism of the pro-oxidant
heme to the radical scavenging bile pigments biliverdin and
bilirubin. Seu et al.105 reported that increased numbers of HO-1
promoter region GT(n) repeats correlated with higher levels of
soluble CD4 during highly active antiretroviral therapy, as well as a
higher mean viral load off-therapy in African-Americans but not
Caucasians. These authors also demonstrated that HO-1 GT(n)
microsatellite polymorphism is associated with HO-1 expression
levels. Ritonavir, an HIV protease inhibitor, has been shown to
promote apoptotic cell death. Ritonavir enhances HO-1 mRNA
levels and protein expression in DLD-1 colon carcinoma cells.106
Hemin, a critical component of hemoglobin, ameliorates HIV-1
infection via induction of HO-1; treatment of monocytes with
hemin was found to substantially inhibit HIV replication.107,108
Similarly, thiamine deﬁciency produces region-speciﬁc neuronal
loss and HO-1 induction in microglia.85,86 Thiamine administration
inhibits further neuronal loss and the induction of HO-1-positive
microglia, but other microglial changes persist.109
Prostaglandins (PGs) play a role in inﬂammatory processes.
Cyclooxygenase (COX) participates in the conversion of arachi-
donic acid into PGs. Increased levels of the brain markers of
neuroinﬂammation and arachidonic acid metabolism are reported
in the brains of HIV-1-infected transgenic rats.110 In vitro, co-
cultures of HIV-infected macrophages and brain endothelium have
shown upregulation of COX-2 expression.111 Extracellular HIV Tat
was found to induce COX-2 mRNA and protein expression, as well
as PGE2 synthesis in astrocytoma cell lines and primary human
astrocytes.112 COX-2 inhibitors attenuated HIV Tat-induced
alterations in occluding expression at the blood–brain barrier,113
prevented the apoptotic death typically produced by HIV-1 gp120
in the neo-cortex,114 and reduced the level of PGE2, thereby
reversing T cell anergy.115 Moreover, the expression of COX-2
mRNA and PGE2 are selectively increased in vulnerable regions
during the symptomatic stages of TD encephalopathy in animal
models.116 Upregulation of 15-hydroxyprostaglandin dehydroge-
nase (15-PGDH) expression was observed in breast cancer cell lines
transfected with THTR2, and downregulation was observed after
suppression of THTR2 with siRNA vectors.117 The overexpression of
15-PGDH inhibited interleukin 1b-induced COX-2 expression.118
Benfotiamine inhibited the expression of COX-2 in endotoxin-
induced uveitis in rats.119 Benfotiamine also blocked the expres-
sion of COX-2 and its PGE2 product in murine macrophages in a
lipopolysaccharide (LPS)-induced cytotoxicity model.41
Reactive oxygen species (ROS) are produced by activated
phagocytes as a part of their microbicidal activities. Depressed
neutrophil superoxide production has been demonstrated in HIV-1
infection.120 Oxidative stress in erythrocytes is associated with the
progression of HIV disease; in the advanced stages, superoxide
dismutase (SOD) activity is increased, while glutathione (GSH) is
decreased at advanced HIV stages.121 Selenium stimulation of GSH
activity decreases HIV-1 activation.122 Lipid peroxide levels have
also been found to be signiﬁcantly higher in HIV-positive
patients.123 Restoration of the GSH levels reverses the HIV-1
protein-mediated effects on superoxide, nitric oxide (NO), and
vasorelaxation.124 Similarly, oxidative stress is associated with
region-speciﬁc neuronal death, and lipid peroxidation products
accumulate in the remaining thalamic neurons after 11 days in
TD animal models.125 Cardiac oxidative stress is involved in
TD-induced heart failure rats; intracellular cardiac superoxide,
Thiamine & Benfotiami ne Human  Immunod efici ency  Virus
Angioten sino gen PAR P Acva on Reacve oxyg en spec ies Gly cog en Synt hetase  Kinase  3 Vasc ular  Endoth elial  Growth Factor
Poly(AD P-ribo syl) polymerase-1 Ser 9 Tyros ine
Inac ve      Ac ve
Angioten sin  I           NAD+, NADPH, ATP p53 a nd Caspase        Mito chon drial dy sfunc on       MAPK Angiog enesis
Endothelial Cel ls
Angioten sin  II                              COX-2, iNOS,  PGE2, NO, and  inﬂammato ry cy tok ines MMPs
(Mat rix metall oprotei ns)
Degradaon P roducts CE LL DEAT H                                                                      INFLAMMATION CELL GR OWTH  DEGRAD ATION
& DIFFER ENTIAT ION                       
Red Color:  Ac vate d, Increased.
Solid Blue Color :  Aenuated, D ecreased.
Figure 1. The role of thiamine in HIV infection.
K.V.Q. Lu’o’ng, L.T.H. Nguyeˆ˜n / International Journal of Infectious Diseases 17 (2013) e221–e227e224SOD protein, and H2O2 contents are increased, while GSH
peroxidase activity is decreased.126 Thiamine inhibits lipid
peroxidation and the free-radical oxidation of oleic acid in rat
liver microsomes in vitro.127 In one study, male Wistar rats were
intoxicated with a dose of ethanol, and changes in the levels of
malondialdehyde (MDA), GSH, and vitamin E were measured to
evaluate the function of the antioxidant system of the liver; these
levels were improved in the thiamine-treated group.128 Thiamine
supplementation suppresses paraquat-induced manganese-con-
taining SOD and glucose-6-phosphate dehydrogenase in vitro.129
Nitric oxide synthase (NOS) synthesizes NO, which regulates a
variety of important physiological responses, including cell
migration, the immune response, and apoptosis. NO affects the
development and function of the CNS. HIV-1 gp120 induces
oxidative stress in human retinal pigment epithelial cells by
stimulating the production of MDA and NO; this production is
mediated by the upregulation of inducible NOS (iNOS) expression
in AIDS-associated retinopathy.130 An increased density of neurons
that contain nicotinamide adenine dinucleotide phosphate
(NADPH) diaphorase and NOS was observed in the cerebral cortex
of patients with HIV-1 infection and a history of drug abuse.131
Administration of the COX-2 inhibitor NS-398 attenuated Tat-
mediated upregulation of mRNA and the expression of inﬂamma-
tory mediator proteins, such as monocyte chemoattractant protein
1, interleukin 1beta, tumor necrosis factor alpha, and iNOS.132 HIV
protease inhibitors signiﬁcantly impair vasomotor function and
reduce endothelial NOS (eNOS) expression in porcine and human
coronary artery endothelial cells.133 HIV-1 gp120 stimulates pro-
inﬂammatory cytokine-mediated pain states via activation of
neuronal NOS (nNOS).134 Ascorbate supplementation prevents the
deleterious upregulation of iNOS, as well as the associated
neuronal and astrocytic protein expression and structural changes
caused by gp120 in human brain cell cultures.135 eNOS gene
deletion restores blood–brain barrier integrity and attenuates
neurodegeneration in the TD mouse brain.86 Benfotiamine inhibits
iNOS expression in endotoxin-induced uveitis in rats.110 Benfo-
tiamine has also been found to inhibit iNOS expression in an LPS-
induced cytotoxicity model in murine macrophages.136 Thiamine
improves GSH levels in acutely alcoholic rats.128Figure 1 illustrates the beneﬁcial role of thiamine in HIV
infection.
4. Conclusions
The relationship between thiamine and HIV infection is
discussed above. Thiamine may serve a beneﬁcial role in HIV
infection. Genetic studies have provided the opportunity to
determine which proteins link thiamine to HIV pathology. Thiamine
also affects HIV through non-genomic mechanisms. It is important
to check the thiamine levels of HIV-infected patients. Further
investigation of the effect of thiamine on HIV infection is needed.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Tang AM, Graham NM, Kirby AJ, McCall LD, Willett WC, Saah AJ. Dietary
micronutrient intake and risk of progression to acquired immunodeﬁciency
syndrome (AIDS) in human immunodeﬁciency virus type 1 (HIV-1)-infected
homosexual men. Am J Epidemiol 1993;138:937–51.
2. Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake
and acquired immune deﬁciency syndrome in HIV-seropositive homosexual
men. J Acquir Immune Deﬁc Syndr 1993;6:949–58.
3. Villamor E, Msamanga G, Spiegelman D, Antelman G, Peterson KE, Hunter DJ,
Fawzi WW. Effect of multivitamin and vitamin A supplements on weight gain
during pregnancy among HIV-1-infected women. Am J Clin Nutr 2002;76:
1082–90.
4. Merchant AT, Msamanga G, Villamor E, Saathoff E, O’brien M, Hertzmark E,
et al. Multivitamin supplementation of HIV-positive women during pregnancy
reduces hypertension. J Nutr 2005;135:1776–81.
5. Villamor E, Saathoff E, Bosch RJ, Hertzmark E, Baylin A, Manji K, et al. Vitamin
supplementation of HIV-infected women improves postnatal child growth. Am
J Clin Nutr 2005;81:880–8.
6. Kawai K, Kupka R, Mugusi F, Aboud S, Okuma J, Villamor E, et al. A randomized
trial to determine the optimal dosage of multivitamin supplements to reduce
adverse pregnancy outcomes among HIV-infected women in Tanzania. Am J
Clin Nutr 2010;91:391–7.
7. Tang AM, Graham NMH, Saah AJ. Effects of micronutrient intake on survival in
human immunodeﬁciency virus type 1 infection. Am J Epidemiol 1998;143:
1244–56.
8. Tattevin P, Souala F, Revest M, Michelet C, Taussig D. Confusion, memory
disorders, and ophthalmoparesis in a patient with AIDS. Lancet 2006;367:368.
9. Cisse´ AF, Camara N, Diallo LL, Morel Y, Kone´ S, Camara MI, et al. [Gayet–
Wernicke’s encephalopathy. A study of 13 cases observed in a refugee popu-
lation hospitalized at the Conakry Teaching Hospital] (in French). Bull Soc
Pathol Exot 2008;101:402–3.
K.V.Q. Lu’o’ng, L.T.H. Nguyeˆ˜n / International Journal of Infectious Diseases 17 (2013) e221–e227 e22510. Cognat E, Hainque E, Mesnage V, Levy R. [Severe dysautonomia revealing
Wernicke’s encephalopathy] (in French). Rev Neurol (Paris) 2011;167:250–3.
11. Mouly S, Khuong MA, Cabie A, Saimot AG, Coulad JP. Beri-Beri and thiamine
deﬁciency in HIV infection. AIDS 1996;10:931–2.
12. Butterworth RF, Gaudreau C, Vincelette J, Bourgault AM, Lamothe F, Nutini AM.
Thiamine deﬁciency and Wernicke’s encephalopathy in AIDS. Metab Brain Dis
1991;6:207–12.
13. Mu¨ri RM, Von Overbeck J, Furrer J, Ballmer PE. Thiamin deﬁciency in HIV-
positive patients: evaluation by erythrocyte transketolase activity and thia-
min pyrophosphate effect. Clin Nutr 1999;18:375–8.
14. Shanina E, Gelman B, Smith RG. Thiamine deﬁciency in HIV associated NRTI
neuropathy. Ann Neurol 2008;64:S62.
15. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside
analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999;16:733–5.
16. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic
acidosis and thiamine administration in an HIV-infected patient on HAART. Int
J STD AIDS 2001;12:407–9.
17. Koch HJ. [Fatty liver and serum lactate elevation in an HIV patient—is the
routine determination of thiamine and riboﬂavin during HAART useful?] (in
German) Dtsch Med Wochenschr 2003;128:1134.
18. Bowers JM, Bert-Moreno A. Treatment of HAART-induced lactic acidosis with B
vitamin supplements. Nutr Clin Pract 2004;19:375–8.
19. Pedrol E, Ribell M, Deig E, Villa`Mdel C, Miro´ O, Garrabou G, Soler A. [Treatment
of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under
nucleoside reverse transcriptase inhibitors] (in Spanish). Med Clin (Barc)
2005;125:201–4.
20. Antal J, Pesti M. The dose-dependent H2O2 stress response promotes increased
survival for Schizosaccharomyces pombe cells expressing HIV-1 Vpr. Folia
Microbiol (Praha) 2006;51:406–12.
21. Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi
K. Disulﬁde-mediated apoptosis of human T-lymphotropic virus type I (HTLV-
I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spas-
tic paraparesis. Antivir Ther 2009;14:533–42.
22. Shoji S, Furuishi K, Ogata A, Yamataka K, Tachibana K, Mukai R, et al. An
allosteric drug, o,o0-bismyristoyl thiamine disulﬁde, suppresses HIV-1 repli-
cation through prevention of nuclear translocation of both HIV-1 Tat and NF-
kappa B. Biochem Biophys Res Commun 1998;249:745–53.
23. Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M, Yamataka K. Thiamine
disulﬁde as a potent inhibitor of human immunodeﬁciency virus (type 1)
production. Biochem Biophys Res Commun 1994;205:967–75.
24. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular
hypertrophy, repair, and remodeling. Hypertension 1994;23:258–68.
25. Oullette DR, Kelly JW, Anders GT. Serum angiotensin-converting enzyme level
is elevated in patients with human immunodeﬁciency virus infection. Arch
Intern Med 1992;152:321–4.
26. Singer F, Talavera W, Zumoff B. Elevated levels of angiotensin-converting
enzyme in Pneumocystis carinii pneumonia. Chest 1989;95:803–6.
27. Bird JE, Durham SK, Giancarli MR, Gitlitz PH, Pandya DG, Dambach DM, et al.
Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol
1998;9:1441–7.
28. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients
with human immunodeﬁciency virus nephropathy. Am J Kidney Dis 1996;28:
202–8.
29. Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long-
term renal survival in HIV-associated nephropathy with angiotensin-convert-
ing enzyme inhibition. Kidney Int 2003;64:1462–71.
30. Auroj K, Pathmanand C, Sueblinvong V, Thisyakom C, Chotivitayatarakom P.
Ventricular functions in children with human immunodeﬁciency virus infec-
tion after ACE inhibitors. Southeast Asian J Trop Med Public Health 1997;28:
375–9.
31. Margolin A, Avants SK, Setaro JF, Rinder HM, Grupp L, Cocaine HIV. and their
cardiovascular effects: is there a role for ACE inhibitor therapy? Drug Alcohol
Depend 2000;61:35–45.
32. Kozlowski S, Corr M, Takeshita T, Boyd LF, Pendleton CD, Germain RN, et al.
Serum angiotensin-1 converting enzyme activity processes a human immu-
nodeﬁciency virus 1 gp160 peptide for presentation by major histocompati-
bility complex class I molecules. J Exp Med 1992;175:1417–22.
33. Hastings MM, Van JL. Sodium deprivation during thiamin deﬁciency in rats:
hormonal, histological, and behavioral responses. J Nutr 1981;111:1955–63.
34. Tanaka T, Sohmiya K, Kono T, Terasaki F, Horie R, Ohkaru Y, et al. Thiamine
attenuates the hypertension and metabolic abnormalities in CD36-defective
SHR: uncoupling of glucose oxidation from cellular entry accompanied with
enhanced protein O-GlcNAcylation in CD36 deﬁciency. Mol Cell Biochem
2007;299:23–35.
35. Furlini G, Re MC, La Placa M. Increased poly(ADP-ribose)polymerase activity in
cells infected by human immunodeﬁciency virus type 1. Microbiologica
1991;14:141–8.
36. Wiley CA, Achim CL, Hammond R, Love S, Masliah E, Radhakrishnan L, et al.
Damage and repair of DNA in HIV encephalitis. J Neuropathol Exp Neurol
2000;59:955–65.
37. Ha HC, Juluri K, Zhou Y, Leung S, Hermankova M, Snyder SH. Poly(ADP-ribose)
polymerase 1 is required for efﬁcient HIV-1 integration. PNAS 2001;98:3364–8.
38. Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Inada Y, et al. Poly(ADP-
ribose) polymerase 1 is required for integration of the human immunodeﬁ-
ciency virus type 1 genome near centromeric alphoid DNA in human and
murine cells. Biochem Biophys Res Commun 2005;334:412–7.39. Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Ikuta K, Yoshihara K. RNA
interference directed against poly(ADP-ribose) polymerase 1 efﬁciently sup-
presses human immunodeﬁciency virus type 1 replication in human cells. J
Virol 2004;78:8931–4.
40. Shin BH, Choi SH, Cho EY, Shin MJ, Hwang KC, Cho HK, et al. Thiamine
attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyo-
cytes. Mol Cells 2004;18:133–40.
41. Yadav UC, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfo-
tiamine, a fat soluble vitamin B1 analogue, in the lipopolysaccharide-induced
cytotoxic signals in murine macrophages. Free Radic Biol Med 2010;48:1423–34.
42. Fre´de´rich M, Delvaux D, Gigliobianco T, Gangolf M, Dive G, Mazzucchelli G,
et al. Thiaminylated adenine nucleotides. FEBS J 2009;276:3256–68.
43. Tanaka T, Yamamoto D, Sato T, Tanaka S, Usui K, Manabe M, et al. Adenosine
thiamine triphosphate (AThTP) inhibits poly(ADP-ribose) polymerase 1
(PARP-1) activity. J Nutr Sci Vitaminol 2011;57:192–6.
44. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr
of human immunodeﬁciency virus type 1 with cellular transcription factor Sp1
and trans-activation of viral long terminal repeat. J Biol Chem 1995;270:
25564–9.
45. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A
cooperative interaction between NF-kB and Sp1 is required for HIV-1 enhanc-
er activation. EMBO J 1993;12:3551–8.
46. Muckenfuss H, Kaiser JK, Krebil E, Battenberg M, Schwer C, Cichutek K, et al.
Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene.
Nucleic Acids Res 2007;35:3784–96.
47. Guo X, Roldan A, Hu J, Wainberg MA, Liang C. Mutation of the Sp1 sequence
impairs both multimerization and membrane-binding activities of human
immunodeﬁciency virus type 1 Gag. J Virol 2005;79:1803–12.
48. Nabokina SM, Said HM. Characterization of the 50-regulatory region of the
human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol
Gastrointest Liver Physiol 2004;287:G822–9.
49. Nabokina SM, Reidling JC, Said HM. Differentiation-dependent up-regulation
of intestinal thiamin uptake: cellular and molecular mechanisms. J Biol Chem
2005;280:32676–82.
50. Thakur BK, Chandra A, Dittrich T, Welte K, Chandra P. Inhibition of SIRT1 by
HIV-1 viral protein Tat results in activation of p53 pathway. Biochem Biophys
Res Commun 2012;424:245–50.
51. Yan H, Liu N, Zhao Z, Zhang X, Xu H, Shao B, Yan W. Expression and puriﬁcation
of human TAT-p53 fusion protein in Pichia pastoris and its inﬂuence on HepG2
cell apoptosis. Biotechnol Lett 2012;34:1217–23.
52. Imbeault M, Ouellet M, Tremblay MJ. Microarray study reveals that HIV-1
induces rapid type-I interferon-dependent p53 mRNA up-regulation in human
primary CD4+ T cells. Retrovirology 2009;6:5.
53. Mukerjee R, Deshmane SL, Fan S, Del Valle L, White MK, Khalili K, et al.
Involvement of the p53 and p73 transcription factors in neuroAIDS. Cell Cycle
2008;7:2682–90.
54. Jayadev S, Yun B, Nguyen H, Yokoo H, Morrison RS, Garden GA. The glial
response to CNS HIV infection includes p53 activation and increased expres-
sion of p53 target genes. J Neuroimmune Pharmacol 2007;2:359–70.
55. Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power
C. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration.
J Neurosci 2007;27:3703–11.
56. Lo PK, Chen JY, Tang PP, Lin J, Lin CH, Su LT, et al. Identiﬁcation of a mouse
thiamine transporter gene as a direct transcriptional target for p53. J Biol Chem
2001;276:37186–93.
57. McLure KG, Takagi M, Kastan MB. NAD+ modulates p53 DNA binding speciﬁc-
ity and function. Mol Cell Biol 2004;24:9958–67.
58. Yang Z, Ge J, Yin W, Shen H, Liu H, Guo Y. [The expression of p53, MDM2 and
Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or
elevated pressure] (in Chinese). Yan Ke Xue Bao 2004;20:259–63.
59. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol 2008;615:13–23.
60. James HJ, Sharer LR, Zhang Q, Wang HG, Epstein LG, Reed JC, Gelbard HA.
Expression of caspase 3 in brains from paediatric patients with HIV-1 enceph-
alitis. Neuropathol Appl Neurobiol 1999;25:380–6.
61. Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apopto-
sis in cultured endothelial cells is mediated by caspases. Blood 2000;96:
1438–42.
62. Cicala C, Arthos J, Rubbert A, Selig S, Wildt K, Cohen OJ, Fauci AS. HIV-1
envelope induces activation of caspase 3 and cleavage of focal adhesion kinase
in primary human CD4+ T cells. Proc Natl Acad Sci U S A 2000;97:1178–83.
63. Garg H, Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-
dependent mitochondrial depolarization, which is inhibited by HIV protease
inhibitor nelﬁnavir. J Leukoc Biol 2006;79:351–62.
64. Bellet V, Duval R, Delebasse´e S, Cook-Moreau J, Bosgiraud C. AZT inhibits visna/
maedi virus-induced apoptosis. Arch Virol 2004;149:583–601.
65. Liu S, Huang H, Lu X, Golinski M, Comesse S, Watt D, et al. Down-regulation of
thiamine transporter THTR2 gene expression in breast cancer and its associa-
tion with resistance to apoptosis. Mol Cancer Res 2003;1:665–73.
66. Chornyy S, Parkhomenko J, Chorna N. Thiamine deﬁciency caused by thiamine
antagonists triggers upregulation of apoptosis inducing factor gene expression
and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-
12 cells. Acta Biochim Pol 2007;54:315–22.
67. Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, et al.
Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice
through protein kinase B/Akt-mediated potentiation of angiogenesis and
inhibition of apoptosis. Diabetologia 2006;49:405–20.
K.V.Q. Lu’o’ng, L.T.H. Nguyeˆ˜n / International Journal of Infectious Diseases 17 (2013) e221–e227e22668. Kang KD, Majid AS, Kim KA, Kang K, Ahn HR, Nho CW, Jung SH. Sulbutiamine
counteracts trophic factor deprivation induced apoptotic cell death in trans-
formed retinal ganglion cells. Neurochem Res 2010;35:1828–39.
69. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-medi-
ated activation of glycogen synthase kinase 3beta contributes to Tat-mediated
neurotoxicity. J Neurochem 1999;73:578–86.
70. Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, Kova´cs AD, et al. Human
immunodeﬁciency virus-encoded Tat activates glycogen synthase kinase
3beta to antagonize nuclear factor-kappaB survival pathway in neurons.
Eur J Neurosci 2006;23:2623–34.
71. Nguyen TB, Lucero GR, Chana G, Hult BJ, Tatro ET, Masliah E, et al. Glycogen
synthase kinase 3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent
human immunodeﬁciency virus-mediated neurotoxicity in primary human
neurons. J Neurovirol 2009;15:434–8.
72. Zhao J, Sun X, Yu Z, Pan X, Gu F, Chen J, et al. Exposure to pyrimidine increases
beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthe-
tase kinase 3 activity in the brain. Neurotox Res 2010;19:575–83.
73. Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, et al. Powerful beneﬁcial effects of
benfotiamine on cognitive impairment and beta-amyloid deposition in amy-
loid precursor protein/presenilin-1 transgenic mice. Brain 2010;133:1342–51.
74. Mellanen L, Ingman T, La¨hdevirta J, Lauhio A, Ainamo A, Konttinen YT, et al.
Matrix metalloproteinases-1, -3, and -8 and myeloperoxidase in saliva of
patients with human immunodeﬁciency virus infection. Oral Dis 1996;2:
263–71.
75. Mellanen L, La¨hdevirta J, Tervahartiala T, Meurman JH, Sorsa T. Matrix metal-
loproteinases-7, -8, -9, -25, and -26 and CD43, -45, and -68 cell-markers in
HIV-infected patients’ saliva and gingival tissue. J Oral Pathol Med 2006;35:
530–9.
76. Naesse EP, Schreurs O, Helgeland K, Steinsvoll S. Matrix metalloproteinases
and their inhibitors in gingival mast cells in persons with and without human
immunodeﬁciency virus infection. J Peridontal Res 2003;38:575–82.
77. Ahuja TS, Gopalani A, Davies P, Ahuja H. Matrix metalloproteinase 9 expres-
sion in renal biopsies of patients with HIV-associated nephropathy. Nephron
Clin Pract 2003;95:c100–4.
78. Jo¨rg A, Grubert T, Grimm T, Guenzi E, Naschberger E, Samson E, et al. Maternal
HIV type 1 infection suppresses MMP-1 expression in endothelial cells of
uninfected newborns: nonviral vertical transmission of HIV type 1-related
effects. AIDS Res Hum Retroviruses 2005;21:940–4.
79. Ragin AB, Wu Y, Ochs R, Scheidegger R, Cohen BA, McArthur JC, et al. Serum
matrix metalloproteinase levels correlate with brain injury in human immu-
nodeﬁciency virus infection. J Neurovirol 2009;15:275–81.
80. Conant K, McArthur JC, Grifﬁn DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal
ﬂuid levels of MMP-2, 7, and 9 are elevated in association with human
immunodeﬁciency virus dementia. Ann Neurol 1999;46:391–8.
81. Louboutin JP, Reyes BA, Agrawal L, Van Bockstaele EJ, Strayer DS. HIV-1 gp120
upregulates matrix metalloproteinases and their inhibitors in a rat model of
HIV encephalopathy. Eur J Neurosci 2011;34:2015–23.
82. Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, et al.
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-
metalloproteinase in endothelial cells and induction of vascular permeability
in vivo by human immunodeﬁciency virus-1 Tat protein and basic ﬁbroblast
growth factor. Mol Biol Cell 2001;12:2934–46.
83. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, D’Agostino C, et al.
Antiretroviral therapy inhibits matrix metalloproteinase 9 from blood mono-
nuclear cells of HIV-infected patients. AIDS 2007;21:677–84.
84. Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, Lichtner M, et al.
Anti-HIV drugs decrease the expression of matrix metalloproteinases in
astrocytes and microglia. Brain 2004;127:398–407.
85. Calingasan NY, Gibson GE. Dietary restriction attenuates the neuronal loss,
induction of heme oxygenase-1 and blood–brain barrier breakdown induced
by impaired oxidative metabolism. Brain Res 2000;885:62–9.
86. Beauchesne E´, Desjardins P, Hazell AS, Butterworth RF. eNOS gene deletion
restores blood–brain barrier integrity and attenuates neurodegeneration in
the thiamine-deﬁcient mouse brain. J Neurochem 2009;111:452–9.
87. Kohda Y, Shirakawa H, Yamane K, Otsuka K, Kono T, Terasaki F, Tanaka T.
Prevention of incipient diabetic cardiomyopathy by high-dose thiamine.
J Toxicol Sci 2008;33:459–72.
88. Tarallo S, Beltramo E, Berrone E, Dentelli P, Porta M. Effects of high glucose and
thiamine on the balance between matrix metalloproteinases and their tissue
inhibitors in vascular cells. Acta Diabetol 2010;47:105–11.
89. Kobayashi T, Notoya K, Nakamura A, Akimoto K. Fursultiamine, a vitamin B1
derivative, enhances chondroprotective effects of glucosamine hydrochloride
and chondroitin sulfate in rabbit experimental osteoarthritis. Inﬂamm Res
2005;54:249–55.
90. Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A, et al. HIV-tat
protein is a heparin-binding angiogenic growth factor. Oncogene 1996;12:
289–97.
91. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, et al. The
angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR
receptor on vascular endothelial cells. Nat Med 1996;2:1371–5.
92. Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, et al. HIV-1 Tat
mimetic of VEGF correlates with increased microvessels density in AIDS-
related diffuse large B-cell and Burkitt lymphomas. J Hematop 2008;1:3–10.
93. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial
growth factor/vascular permeability factor is an autocrine growth factor for
AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 1997;94:979–84.94. Mercie´ P, Devianne I, Viallard JF, Faure I, Pellegrin I, Leng B, et al. Vascular
endothelial growth factor (VEGF165) plasma level increase with immunode-
pression in AIDS patients with Kaposi’s sarcoma. Microvasc Res 1999;57:208–10.
95. Samaniego F, Young D, Grimes C, Prospero V, Christoﬁdou-Solomidou M,
DeLisser HM, et al. Vascular endothelial growth factor and Kaposi’s sarcoma
cells in human skin grafts. Cell Growth Differ 2002;13:387–95.
96. Sporer B, Koedel U, Paul R, Eberle J, Arendt G, Pﬁster HW. Vascular endothelial
growth factor (VEGF) is increased in serum, but not in cerebrospinal ﬂuid in
HIV associated CNS diseases. J Neurol Neurosurg Psychiatry 2004;75:298–300.
97. Nakamura S, Murakami-Mori K, Rao N, Weich HA, Rajeev B. Vascular endo-
thelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi’s
sarcoma-derived spindle cells. J Immunol 1997;158:4992–5001.
98. Mitola S, Sozzani S, Luini W, Primo L, Borsatti A, Weich H, Bussolino F. Tat-
human immunodeﬁciency virus 1 induces human monocyte chemotaxis by
activation of vascular endothelial growth factor receptor 1. Blood 1997;90:
1365–72.
99. Korgaonkar SN, Feng X, Ross MD, Lu TC, D’Agati V, Iyengar R, et al. HIV-1
upregulates VEGF in podocytes. J Am Soc Nephrol 2008;19:877–83.
100. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease
VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia
2006;8:889–95.
101. Nakagawa H, Yoneda M, Maeda A, Umehara F, Kuriyama M. [Thiamine
deﬁciency polyneuropathy after gastrectomy associated with high level of
serum vascular endothelial growth factor (VEGF). A case report] (in Japanese).
Rinsho Shinkeigaku 2004;44:91–5.
102. Imai N, Kubota M, Saitou M, Yagi N, Serizawa M, Kobari M. Increase of serum
vascular endothelial growth factors in wet beriberi: two case reports. Intern
Med 2012;51:929–32.
103. Kihm LP, Mu¨ller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, et al. Benfo-
tiamine protects against peritoneal and kidney damage in peritoneal dialysis.
J Am Soc Nephrol 2011;22:914–26.
104. Katare R, Caporali A, Emanueli C, Madeddu P. Benfotiamine improves func-
tional recovery of the infarcted heart via activation of pro-survival G6PD/Akt
signaling pathway and modulation of neurohormonal response. J Mol Cell
Cardiol 2010;49:625–38.
105. Seu L, Burt TD, Witte JS, Martin JN, Deeks SG, McCune JM. Variations in the
heme oxygenase-1 microsatellite polymorphism are associated with plasma
CD14 and viral load in HIV-infected African-Americans. Genes Immun
2012;13:258–67.
106. Mu¨hl H, Paulukat J, Ho¨ﬂer S, Hellmuth M, Frazen R, Pfeilschifter J. The HIV
protease inhibitor ritonavir synergizes with butyrate for induction of apopto-
tic cell death and mediates expression of heme oxygenase 1 in DLD-1 colon
carcinoma cells. Br J Pharmacol 2004;143:890–8.
107. Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme
oxygenase 1 induction. J Immunol 2006;176:4252–7.
108. Shankaran P, Vlkova L, Liskova J, Melkova Z. Heme arginate potentiates latent
HIV-1 reactivation while inhibiting the acute infection. Antiviral Res 2011;92:
434–46.
109. Ke ZJ, DeGiorgio LA, Volpe BT, Gibson GE. Reversal of thiamine deﬁciency-
induced neurodegeneration. J Neuropathol Exp Neurol 2003;62:195–207.
110. Basselin M, Ramadan E, Igarashi M, Chang L, Chen M, Kraft AD, et al. Imaging
upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats.
J Cereb Blood Flow Metab 2011;31:486–93.
111. Pereira CF, Boven LA, Middel J, Verhoef J, Nottet HS. Induction of cyclooxy-
genase 2 expression during HIV-1-infected monocyte-derived macrophage
and human brain microvascular endothelial cell interactions. J Leukoc Biol
2000;68:423–8.
112. Blanco A, Alvarez S, Fresno M, Mun˜oz-Ferna´ndez MA. Extracellular HIV-Tat
induces cyclooxygenase 2 in glial cells through activation of nuclear factor of
activated T cells. J Immunol 2008;180:530–40.
113. Pu H, Hayashi K, Andras IE, Eum SY, Hennig B, Toborek M. Limited role of COX-
2 in HIV Tat-induced alterations of tight junction protein expression and
disruption of the blood brain barrier. Brain Res 2007;1184:333–44.
114. Bagetta G, Corasaniti MT, Paoletti AM, Berliocchi L, Nistico` R, Giammarioli AM,
et al. HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced
expression of cyclo-oxygenase type 2 (COX-2). Biochem Biophys Res Commun
1998;244:819–24.
115. Rahmouni S, Aandahl EM, Nayjib B, Zeddou M, Giannini S, Verlaet M, et al.
Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in
retrovirus-induced T-cell dysfunction in mice. Biochem J 2004;384:469–76.
116. Gu B, Desjardins P, Butterworth RF. Selective increase of neuronal cyclooxy-
genase 2 (COX-2) expression in vulnerable brain regions of rats with experi-
mental Wernicke’s encephalopathy: effect of numesulide. Metab Brain Dis
2008;23:175–87.
117. Liu S, Stromberg A, Tai HH, Moscow JA. Thiamine transporter gene expression
and exogenous thiamine modulate the expression of genes involved in drug
and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2004;2:
477–87.
118. Tai HH, Tong M, Ding Y. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH)
and lung cancer. Prostaglandins Other Lipid Mediat 2007;83:203–8.
119. Yaday UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced
uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest
Ophthalmol Vis Sci 2009;50:2276–82.
120. Pitrak DL, Bak PM, DeMarais P, Novak RM, Andersen BR. Depressed neutrophil
superoxide production in human immunodeﬁciency virus infection. J Infect Dis
1993;167:1406–10.
K.V.Q. Lu’o’ng, L.T.H. Nguyeˆ˜n / International Journal of Infectious Diseases 17 (2013) e221–e227 e227121. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S.
Oxidative stress in blood of HIV infected patients. Clin Chim Acta 1996;
255:107–17.
122. Sappey C, Legrand-Poels S, Best-Belpomme M, Favier A, Rentier B, Piette J.
Stimulation of glutathione peroxide activity decreases HIV type 1 activation
after oxidative stress. AIDS Res Hum Retroviruses 1994;10:1451–61.
123. Allard JP, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma
antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998;
67:143–7.
124. Kline ER, Kleinhenz DJ, Liang B, Dikalov S, Guidot DM, Hart CM, et al. Vascular
oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are
reversed by glutathione restoration. Am J Physiol Heart Circ Physiol 2008;
294:H2792–804.
125. Calingasan NY, Chun WJ, Park LC, Gibson GE. Oxidative stress is associated
with region-speciﬁc neuronal death during thiamine deﬁciency. J Neuropathol
Exp Neurol 1999;58:946–58.
126. Gioda CR, de Oliveira Barreto T, Prı´mola-Gomes TN, de Lima DC, Campos PP,
Capettini Ldos S, et al. Cardiac oxidative stress is involved in heart failure
induced by thiamine deprivation in rats. Am J Physiol Heart Circ Physiol
2010;298:H2039–45.
127. Lukienko PI, Mel’nichenko NG, Zverinskii IV, Zabrodskaya SV. Antioxidant
properties of thiamine. Bull Exp Biol Med 2000;130:874–6.
128. Portari GV, Marchini JS, Vannucchi H, Jordao AA. Antioxidant effect of
thiamine on acutely alcoholized rats and lack of efﬁcacy using thiamine
or glucose to reduce blood alcohol content. Basic Clin Pharmacol Toxicol
2008;103:482–6.129. Jung IL, Kim IG. Thiamine protects against paraquat-induced damage: scav-
enging activity of reactive oxygen species. Environ Toxicol Pharmacol 2003;
15:19–26.
130. Yu QR, Zhang ZP, Zhang H, Lin HT, Li XM, Bai L, Cai WB. Inducible nitric oxide
synthase is involved in the oxidation stress induced by HIV-1 gp120 in human
retina pigment epithelial cells. Chin Med J (Engl) 2008;121:2578–83.
131. Kuljis RO, Shapshak P, Alcabes P, Rodrı´guez de la Vega P, Fujimura R, Petito CK.
Increased density of neurons containing NADPH diaphorase and nitric oxide
synthase in the cerebral cortex of patients with HIV-1 infection and drug
abuse. J NeuroAIDS 2002;2:19–36.
132. Flora G, Pu H, Hennig B, Toborek M. Cyclooxygenase 2 is involved in HIV-1 Tat-
induced inﬂammatory responses in the brain. Neuromolecular Med 2006;8:
337–52.
133. Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on
vasomotor function and endothelial nitric oxide synthase expression. J Acquir
Immune Deﬁc Syndr 2005;39:152–8.
134. Holguin A, O’Connor KA, Biedenkapp J, Campisi J, Wieseler-Frank J, Milligan
ED, et al. HIV-1 gp120 stimulates proinﬂammatory cytokine-mediated pain
facilitation via activation of nitric oxide synthase I (nNOS). Pain 2004;110:
517–30.
135. Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR.
Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neu-
roinﬂammation 2004;1:8.
136. Yadav UC, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfo-
tiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced
cytotoxic signals in murine macrophages. Free Radic Biol Med 2010;48:1423–34.
